Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Kintor Pharmaceutical Ltd ( (HK:9939) ) is now available.
Kintor Pharmaceutical Limited announced that the Phase II stage of its pivotal clinical trial for KX-826 tincture 1.0% has achieved its primary endpoint for treating male adult androgenetic alopecia (AGA) in China. The trial demonstrated statistically significant efficacy and safety, with both 0.5% and 1.0% BID groups showing meaningful improvements in hair growth compared to the placebo group. The Independent Data Monitoring Committee recommended continuing to the Phase III stage without modifications, indicating positive implications for Kintor’s market positioning and potential future offerings.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a pharmaceutical company incorporated in the Cayman Islands, focused on developing innovative treatments for various medical conditions. The company is engaged in the research and development of novel drugs, with a particular emphasis on treatments for androgenetic alopecia (AGA) and other dermatological conditions.
Average Trading Volume: 4,389,997
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.09B
For an in-depth examination of 9939 stock, go to TipRanks’ Overview page.
Trending Articles:
- Daniel Ives Lifts Palantir (PLTR) to New Street-High Price Target, Stock Hits a Fresh 52-Week High
- “Boeing Has Backed Itself Into a Corner,” Says Union, Boeing Stock (NYSE:BA) Gains Anyway
- “You Received a Refund Within 24 Hours”: Elon Musk Claps Back on Sam Altman’s Refund Request, Tesla Stock (NASDAQ:TSLA) Surges